Mizuho Securities Remains a Buy on Merck & Company (MRK)

By Carrie Williams

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRKResearch Report) today and set a price target of $100.00. The company’s shares closed last Thursday at $75.78.

According to TipRanks.com, Goldstein ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.3% and a 33.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, CytomX Therapeutics, and Fate Therapeutics.

Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $98.75, implying a 30.0% upside from current levels. In a report issued on March 30, Leerink Partners also maintained a Buy rating on the stock with a $98.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $92.64 and a one-year low of $65.25. Currently, Merck & Company has an average volume of 13.45M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.